Abstract
Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Current Pharmaceutical Biotechnology
Title:Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Volume: 15 Issue: 7
Author(s): Francisca Araujo, Neha Shrestha, Pedro L. Granja, Jouni Hirvonen, Hélder A. Santos and Bruno Sarmento
Affiliation:
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Abstract: Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Export Options
About this article
Cite this article as:
Araujo Francisca, Shrestha Neha, Granja L. Pedro, Hirvonen Jouni, Santos A. Hélder and Sarmento Bruno, Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects, Current Pharmaceutical Biotechnology 2014; 15 (7) . https://dx.doi.org/10.2174/1389201015666140915150312
DOI https://dx.doi.org/10.2174/1389201015666140915150312 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Secondary Prevention of Ischemic Stroke
Current Drug Targets Synthesis, Biological Evaluation, and QPLD Studies of Piperazine Derivatives as Potential DPP-IV Inhibitors
Medicinal Chemistry Emerging Trends On Drug Delivery Strategy of Momordica charantia against Diabetes and its Complications
Current Drug Delivery Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness
Current Diabetes Reviews Suitable Antibacterial Substances for the Treatment of Urinary Tract Infections
Anti-Infective Agents in Medicinal Chemistry Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology Structure and Ligand-Based Drug Design to Propose Novel α-Glucosidase Inhibitors
Current Bioactive Compounds Recent Advances in Synthetic Chemistry of Diabetic Research
Mini-Reviews in Medicinal Chemistry Lipodystrophy, Insulin Resistance, and Adiponectin Concentration in HIV-Infected Children and Adolescents
Current HIV Research Hidden Hunger of Vitamin E among Healthy College Students: A Cross- Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Current Drug Discovery Technologies Anti-Angiogenesis Drugs in Diabetic Retinopathy
Current Pharmaceutical Biotechnology The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders
Current Drug Metabolism Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy
Current Radiopharmaceuticals